Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
February 19, 2019 09:15 ET
|
Pernix Therapeutics Holdings, Inc.
Transaction that includes the sale of substantially all of Pernix’s assets to be valued at $75.6 million Pernix voluntarily files for Chapter 11 protection Pernix intends to continue to...
Pernix® Therapeutics Reports Third Quarter 2018 Financial Results
November 08, 2018 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and nine...
Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8
November 02, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the Company will report financial...
Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
September 12, 2018 07:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a...
Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek®
August 27, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that in the Company’s litigation against...
Pernix Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and...
Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility
August 01, 2018 09:08 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announces a series of transactions aimed at strengthening its...
Pernix Therapeutics to Report Second Quarter 2018 Financial Results on Thursday, August 9
July 31, 2018 16:15 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial...
Pernix Therapeutics Announces Successful Closing of Transaction Regarding Worldwide Rights to Contrave® for Weight Loss
July 30, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the closing of a transaction in which...
Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss
June 22, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc....